Fosamax and Osteonecrosis of the Jaw: A Clinical Evidence Review
Latest update (2026-05)
FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]
From General Health Information to Targeted Risk Assessment
The legacy context of general health and science information has long served as a foundation for public understanding of medical conditions and treatment options. Within this broad framework, discussions of bone health and pharmaceutical interventions have been standard topics, often presented in accessible formats for diverse audiences. This heritage emphasizes the importance of informed decision-making regarding therapeutic choices, while maintaining a neutral stance on specific outcomes. Transitioning from this general health perspective, attention now turns to a more focused area of inquiry: the relationship between bisphosphonate therapy, specifically Fosamax, and the risk of osteonecrosis of the jaw. This pivot represents a shift from broad educational content to a targeted examination of potential adverse effects associated with long-term medication use. The concern here is not about general health maintenance, but about a specific clinical observation that has emerged in post-marketing surveillance and case reports.
Bridging General Awareness to Clinical Vigilance
The bridge concept connects the legacy of general health information to a specialized risk assessment. While the original context provided foundational knowledge about bone density management, the current focus narrows to a particular complication that has been documented in patients undergoing dental procedures or experiencing oral trauma while on bisphosphonate therapy. This transition maintains academic neutrality by avoiding mechanistic claims, instead highlighting the shift from general awareness to specific clinical vigilance regarding Fosamax exposure and jaw health outcomes. Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its clinical utility in reducing fracture risk is well established, but a serious adverse effect—osteonecrosis of the jaw (ONJ)—has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).
Clinical Presentation and Diagnosis of Osteonecrosis of the Jaw
Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region, often associated with pain, swelling, and infection. The condition can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The diagnosis is primarily clinical, based on the presence of exposed bone in the jaw that persists for more than eight weeks, with no history of radiation therapy to the region. Imaging may support the diagnosis, but the condition is often identified through oral examination and patient history.
Fosamax Pharmacology and Reported Adverse Effects
Fosamax is a nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorption, thereby increasing bone mineral density and reducing fracture risk. Its pharmacology involves binding to hydroxyapatite in bone, where it is taken up by osteoclasts during bone remodeling, leading to osteoclast apoptosis. This mechanism is central to its therapeutic effect but also contributes to adverse effects on bone turnover. The time to onset of ONJ symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping Fosamax, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups, suggesting that background risk factors may contribute (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).
Mechanistic Pathways Linking Fosamax to Osteonecrosis of the Jaw
The exact mechanism by which bisphosphonates like Fosamax contribute to ONJ is not fully understood, but several pathways have been proposed. Bisphosphonates suppress bone turnover by inhibiting osteoclast activity, which may impair the normal remodeling and repair of jawbone, particularly after dental procedures or trauma. The jawbone has unique characteristics, including high bone turnover rates and exposure to oral microbiota, which may make it more susceptible to complications. A multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). Additionally, bisphosphonates may have anti-angiogenic effects, reducing blood supply to the jawbone, and may alter immune responses, increasing susceptibility to infection. The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1), suggesting a cumulative effect on bone turnover suppression.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the link between Fosamax and osteonecrosis of the jaw?
Fosamax (alendronate) is a bisphosphonate that can increase the risk of osteonecrosis of the jaw (ONJ), a condition where jawbone tissue dies and becomes exposed. The risk is higher with long-term use, especially after dental procedures or oral trauma. The exact mechanism is not fully understood but involves suppressed bone turnover and reduced blood supply. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56)
What are the symptoms of osteonecrosis of the jaw?
How can the risk of ONJ be reduced while taking Fosamax?
Maintain good oral hygiene, have regular dental check-ups, and inform your dentist about Fosamax use. For invasive dental procedures, temporary discontinuation of Fosamax may reduce risk. The optimal duration of use is not determined, but for low-risk patients, discontinuation after 3-5 years is considered. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1)
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.